Krystal Biotech Overview
Latest ROE for Krystal Biotech: 17.77% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow17.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, KRYS shows a ROE of 17.77%. That is below the Healthcare sector average of 21.3%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.3%. Krystal Biotech is at 17.77%, which is lower that average. That is roughly 16.6% below the sector mean. Use the comparison chart on this page to see how KRYS stacks up against individual peers as well.
Check the historical chart to see whether KRYS's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Krystal Biotech with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Krystal Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 17.77%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.3%, while KRYS is at 17.77%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
